DURHAM – Aerami Therapeutics has closed more than $22.2 million in equity funding, according to an amended SEC filing signed by the company’s CEO, Steven Thornton, yesterday.
The filing states that the company has raised a total of $22,250,560 from 238 investors and will pay New York-based Aegis Capital $2,221,056 in sales commissions, noting “Warrants to purchase up to 10% of the number of shares sold in the offering will be issued to Placement Agent for nominal consideration.”
The company filing also states that the funds will be used for “working capital and genl corporate purposes, incl officer and employee salaries & director fees.”
Additionally, the filing notes, a portion of proceeds will be used as compensation to the placement agent, Aegis Capital. A director of the company is an affiliate of the placement agent, the filing states.
An earlier SEC filing, dated Sept. 23, also signed by Thornton, reported that the company had raised $2.2 million from 28 investors, and noted that the company could raise up to $20 million.
The company website states “We are advancing a diverse pipeline of inhaled therapies for the treatment of severe respiratory and chronic diseases. Our lead product candidate is inhaled imatinib (AER-901) for the treatment of pulmonary arterial hypertension.”